Phage therapy of non-wound infections

Bacteriophages in Health and Disease

Volumn , Issue , 2012, Pages 203-216

  Burrowes, Ben ^a   Harper, David R ^a  

^a AmpliPhi Biosciences Corp   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878289329     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (99)

1. Abedon, S.T. (2010) The 'nuts and bolts' of phage therapy. Current Pharmaceutical Biotechnology 11, 1.
2. Abedon, S. (2011a) Phage therapy pharmacology: calculating phage dosing. Advances in Applied Microbiology 77, 1-40.
3. Abedon, S. (2011b) Bacteriophages and Biofilms: Ecology, Phage Therapy, Plaques. Nova Science Publishers, New York.
4. Abedon, S.T. (2012) Bacteriophages as drugs: the pharmacology of phage therapy. In: Borysowski, J., Miêdzybrodzki, R. and Górski, A. (eds) Phage Therapy: Current Research and Applications. Caister Academic Press, UK.
5. Abedon, S.T. and Thomas-Abedon, C. (2010) Phage therapy pharmacology. Current Pharmaceutical Biotechnology 11, 28-47.
6. Abedon, S.T., Kuhl, S.J., Blasdel, R.G. and Kutter, E.M. (2011) Phage treatment of human infections. Bacteriophage 1, 66-85.
7. Asheshov, I., Khan, S. and Lahiri, M. (1931) The treatment of cholera with bacteriophage. Indian Medical Gazette 66, 179-184.
8. Asheshov, I.N., Asheshov, I., Khan, S. and Lahiri, M. (1930) Bacteriophage inqu. Report on the work during the period from 1st January to 1st September 1929. Indian Journal of Medical Research 17, 971-984.
9. Babalova, E., Katsitadze, K., Sakvarelidze, L., Imnaishvili, N.S., Sharashidze, T., Badashvili, V., Kiknadze, G., MeÄpariani, A., Gendzekhadze, N. and Machavariani, E. (1968) Preventive value of dried dysentery bacteriophage. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 45, 143-145.
10. Bhowmick, T.S., Koley, H., Das, M., Saha, D.R. and Sarkar, B. (2009) Pathogenic potential of vibriophages against an experimental infection with Vibrio cholerae O1 in the RITARD model. International Journal of Antimicrobial Agents 33, 569-573.
11. Biswas, B., Adhya, S., Washart, P., Paul, B., Trostel, A.N., Powell, B., Carlton, R. and Merril, C.R. (2002) Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycinresistant Enterococcus faecium. Infection and Immunity 70, 204-210.
12. Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., Scheld, M., Spellberg, B. and Bartlett, J. (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clinical Infectious Diseases 48, 1-12.
13. Boyce, J.M., Jackson, M.M., Pugliese, G., Batt, M.D., Fleming, D., Garner, J.S., Hartstein, A.I., Kauffman, C.A., Simmons, M. and Weinstein, R. (1994) Methicillin-resistant Staphylococcus aureus (MRSA): a briefing for acute care hospitals and nursing facilities. Infection Control and Hospital Epidemiology 15, 105-115.
14. Bruttin, A. and Brussow, H. (2005) Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrobial Agents and Chemotherapy 49, 2874-2878.
15. Bull, J., Vimr, E. and Molineux, I. (2010) A tale of tails: sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli. Virology 398, 79-86.
16. Carmody, L.A., Gill, J.J., Summer, E.J., Sajjan, U.S., Gonzalez, C.F., Young, R.F. and LiPuma, J.J. (2010) Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. Journal of Infectious Diseases 201, 264-271.
17. Chan, B. and Abedon, S. (2012) Phage therapy pharmacology: phage cocktails. Advances in Applied Microbiology 78 (in press)
18. Chanishvili, N. and Sharp, R. (2009) A Literature Review of the Practical Application of Bacteriophage Research. Eliava Institute of Bacteriophages, Microbiology and Virology, Tbilisi, Georgia.
19. Chhibber, S., Kaur, S. and Kumari, S. (2008) Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. Journal of Medical Microbiology 57, 1508-1513.
20. Chibani-Chennoufi, S., Sidoti, J., Bruttin, A., Kutter, E., Sarker, S. and Brussow, H. (2004) In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrobial Agents and Chemotherapy 48, 2558-2569.
21. Clokie, M.R.J. and Kropinski, A.M.B. (2009) Bacteriophages: Methods and Protocols: Molecular and Applied Aspects. Humana Press, Totowa, NJ.
22. Comeau, A.M., Tétart, F., Trojet, S.N., Prère, M.F. and Krisch, H. (2007) Phage-antibiotic synergy (PAS): ?-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 2, e799.
23. Curtright, A. and Abedon, S. (2011) Phage therapy: emergent property pharmacology. Journal of Bioanalysis and Biomedicine S6, doi: 10.4172/1948-593X.S6-002 (Epub ahead of print).
24. Dabrowska, K., Switała-Jelen, K., Opolski, A., Weber-Dabrowska, B. and Górski, A. (2005) Bacteriophage penetration in vertebrates. Journal of Applied Microbiology 98, 7-13.
25. Debarbieux, L., Leduc, D., Maura, D., Morello, E., Criscuolo, A., Grossi, O., Balloy, V. and Touqui, L. (2010) Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. Journal of Infectious Diseases 201, 1096-1104.
26. Denou, E., Bruttin, A., Barretto, C., Ngom-Bru, C., Brüssow, H. and Zuber, S. (2009) T4 phages against Escherichia coli diarrhea: potential and problems. Virology 388, 21-30.
27. d'Hérelle, F. (1921) Le microbe bactériophage, agent d'immunité dans la peste et la barbone. Comptes Rendus de l'Académie des Sciences 172, 99-100.
28. d'Hérelle, F. (1922) The Bacteriophage, its Role in Immunity. Williams & Wilkins, Baltimore, MD.
29. d'Hérelle, F. (1929) Studies upon asiatic cholera. Yale Journal of Biology and Medicine 1, 195-219.
30. d'Hérelle, F. (2007) On an invisible microbe antagonistic toward dysenteric bacilli: brief note by M. F. D'Hérelle, presented by Mr. Roux. 1917. Research in Microbiology 158, 553-554.
31. d'Hérelle, F., Malone, R. and Lahiri, M. (1928) The treatment and prophylaxis of infectious diseases of the intestinal tract and of cholera in particular. In: Transaction of the 7th Congress held in British India, December 1927, Far Eastern Association of Tropical Medicine, Vol. II. Thacker, Calcutta, pp. 284-287.
32. Eaton, M.D. and Bayne-Jones, S. (1934) Bacteriophage therapy. Journal of the American Medical Association 103, 1847-1853.
33. Geier, M.R., Trigg, M.E. and Merril, C.R. (1973) Fate of bacteriophage lambda in non-immune germ-free mice. Nature 246, 221-222.
34. Gill, J., Pacan, J., Carson, M., Leslie, K., Griffiths, M. and Sabour, P. (2006) Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle. Antimicrobial Agents and Chemotherapy 50, 2912-2918.
35. Gill, J.J. and Hyman, P. (2010) Phage choice, isolation and preparation for phage therapy. Current Pharmaceutical Biotechnology 11, 2-14.
36. Golshahi, L., Seed, K.D., Dennis, J.J. and Finlay, W.H. (2008) Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. Journal of Aerosol Medicine and Pulmonary Drug Delivery 21, 351-360.
37. Goodridge, L.D. (2010) Designing phage therapeutics. Current Pharmaceutical Biotechnology 11, 15-27.
38. Govind, R., Vediyappan, G., Rolfe, R.D., Dupuy, B. and Fralick, J.A. (2009) Bacteriophagemediated toxin gene regulation in Clostridium difficile. Journal of Virology 83, 12037-12045.
39. Harrison, F. (2007) Microbial ecology of the cystic fibrosis lung. Microbiology 153, 917-923.
40. Häusler, T. (2006) Viruses vs. Superbugs: a Solution to the Antibiotics Crisis? Palgrave Macmillan, Hampshire, UK.
41. Hawkins, C., Harper, D., Burch, D., Anggard, E. and Soothill, J. (2010) Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Veterinary Microbiology 146, 309-313.
42. Heinemann, J.A., Ankenbauer, R.G. and Amabile-Cuevas, C.F. (2000) Do antibiotics maintain antibiotic resistance? Drug Discovery Today 5, 195-204.
43. Heo, Y.J., Lee, Y.R., Jung, H.H., Lee, J.E., Ko, G.P. and Cho, Y.H. (2009) Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrobial Agents and Chemotherapy 53, 2469-2474.
44. Hogardt, M. and Heesemann, J. (2010) Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. International Journal of Medical Microbiology 300, 557-562.
45. Høiby, N., Ciofu, O. and Bjarnsholt, T. (2010) Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiology 5, 1663-1674.
46. Jarvis, W.R. (2010) Prevention and control of methicillin-resistant Staphylococcus aureus: dealing with reality, resistance and resistance to reality. Clinical Infectious Diseases 50, 218-220.
47. Knouf, E.G., Ward, W.E., Reichle, P.A., Bower, A. and Hamilton, P.M. (1946) Treatment of typhoid fever with type specific bacteriophage. Journal of the American Medical Association 132, 134-138.
48. Krueger, A. and Scribner, E. (1941) The bacteriophage: its nature and its therapeutic use. Journal of the American Medical Association 116, 2269-2277.
49. Kutateladze, M. and Adamia, R. (2008) Phage therapy experience at the Eliava Institute. Medecine et Maladies Infectieuses 38, 426-430.
50. Kutter, E. and Sulakvelidze, A. (2005) Bacteriophages: Biology and Applications. CRC Press, Boca Raton, FL.
51. Kutter, E., de Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S. and Abedon, S.T. (2010) Phage therapy in clinical practice: treatment of human infections. Current Pharmaceutical Biotechnology 11, 69-86.
52. Levin, B.R. and Bull, J. (1996) Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. American Naturalist 881-898.
53. Levin, B.R. and Bull, J.J. (2004) Population and evolutionary dynamics of phage therapy. Nature Reviews Microbiology 2, 166-173.
54. Lu, T.K. and Collins, J.J. (2007) Dispersing biofilms with engineered enzymatic bacteriophage. Proceedings of the National Academy of Sciences USA 104, 11197-11202.
55. Lu, T.K. and Collins, J.J. (2009) Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proceedings of the National Academy of Sciences USA. 106, 4629-4634.
56. Matsuzaki, S., Yasuda, M., Nishikawa, H., Kuroda, M., Ujihara, T., Shuin, T., Shen, Y., Jin, Z., Fujimoto, S., Nasimuzzaman, M.D., Wakiguchi, H., Sugihara, S., Sugiura, T., Koda, S., Muraoka, A. and Imai, S. (2003) Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage ?MR11. Journal of Infectious Diseases 187, 613-624.
57. McVay, C.S., Velasquez, M. and Fralick, J.A. (2007) Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrobial Agents and Chemotherapy 51, 1934-1938.
58. Merabishvili, M., Pirnay, J.P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J. and Van Parys, L. (2009) Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4, e4944.
59. Merril, C.R., Biswas, B., Carlton, R., Jensen, N.C., Creed, G.J., Zullo, S. and Adhya, S. (1996) Long-circulating bacteriophage as antibacterial agents. Proceedings of the National Academy of Sciences USA 93, 3188-3192.
60. Morello, E., Saussereau, E., Maura, D., Huerre, M., Touqui, L., Debarbieux, L. and Aziz, R. (2011) Pulmonary bacteriophage therapy on cystic fibrosis strains: first steps towards treatment and prevention. PLoS One 6, e16963.
61. Morison, J. (1932) Bacteriophage in the Treatment and Prevention of Cholera. H.K. Lewis, London, UK.
62. Payne, R.J.H. and Jansen, V.A.A. (2003) Pharmacokinetic principles of bacteriophage therapy. Clinical Pharmacokinetics 42, 315-325.
63. Pirnay, J.P., de Vos, D., Verbeken, G., Merabishvili, M., Chanishvili, N., Vaneechoutte, M., Zizi, M., Laire, G., Lavigne, R. and Huys, I. (2011) The phage therapy paradigm: Prêt-à-Porter or Surmesure? Pharmaceutical Research 28, 934-937.
64. Podschun, R. and Ullmann, U. (1998) Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods and pathogenicity factors. Clinical Microbiology Reviews 11, 589-603.
65. Pouillot, F., Blois, H. and Iris, F. (2010) Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 8, 155-169.
66. Ramesh, V., Fralick, J.A. and Rolfe, R.D. (1999) Prevention of Clostridium difficile-induced ileocecitis with bacteriophage. Anaerobe 5, 69-78.
67. Rapson, M.E., Burden, F.A., Glancey, L.P., Hodgson, D.A. and Mann, N.H. (2008) US Patent Application 2008 0317715.
68. Rhoads, D.D., Wolcott, R.D., Kuskowski, M.A., Wolcott, B.M., Ward, L.S. and Sulakvelidze, A. (2009) Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. Journal of Wound Care 18, 237-238.
69. Slopek, S., Durlakowa, I., Weber-Dabrowska, B., Kucharewicz-Krukowska, A., Dabrowski, M. and Bisikiewicz, R. (1983a) Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Archivum Immunologiae et Therapiae Experimentalis 31, 267-291.
70. Slopek, S., Durlakowa, I., Weber-Dabrowska, B., Kucharewicz-Krukowska, A., Dabrowski, M. and Bisikiewicz, R. (1983b) Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results. Archivum Immunologiae et Therapiae Experimentalis 31, 293-327.
71. Slopek, S., Durlakowa, I., Weber-Dabrowska, B., Dabrowski, M. and Kucharewicz-Krukowska, A. (1984) Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in further 150 cases. Archivum Immunologiae et Therapiae Experimentalis 32, 317-335.
72. Slopek, S., Kucharewicz-Krukowska, A., Weber-Dabrowska, B. and Dabrowski, M. (1985a) Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections. Archivum Immunologiae et Therapiae Experimentalis 33, 261-273.
73. Slopek, S., Kucharewicz-Krukowska, A., Weber-Dabrowska, B. and Dabrowski, M. (1985b) Results of bacteriophage treatment of suppurative bacterial infections. V. Evaluation of the results obtained in children. Archivum Immunologiae et Therapiae Experimentalis 33, 241-259.
74. Slopek, S., Kucharewicz-Krukowska, A., Weber-Dabrowska, B. and Dabrowski, M. (1985c) Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in 370 cases. Archivum Immunologiae et Therapiae Experimentalis 33, 219-240.
75. Slopek, S., Weber-Dabrowska, B., Dabrowski, M. and Kucharewicz-Krukowska, A. (1987) Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Archivum Immunologiae et Therapiae Experimentalis 35, 569-583.
76. Smith, H.W. and Huggins, M. (1982) Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. Journal of General Microbiology 128, 307-318.
77. Smith, H.W. and Huggins, M. (1983) Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. Journal of General Microbiology 129, 2659-2675.
78. Smith, H.W., Huggins, M.B. and Shaw, K.M. (1987a) The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. Journal of General Microbiology 133, 1111-1126.
79. Smith, H.W., Huggins, M.B. and Shaw, K.M. (1987b) Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. Journal of General Microbiology 133, 1127-1135.
80. Smith, J. (1924) The bacteriophage in the treatment of typhoid fever. British Medical Journal 2, 47-49.
81. Soothill, J. (1992) Treatment of experimental infections of mice with bacteriophages. Journal of Medical Microbiology 37, 258-261.
82. Soothill, J. (1994) Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 20, 209-211.
83. Soothill, J., Lawrence, J. and Ayliffe, G. (1988) The efficacy of phages in the prevention of the destruction of pig skin in vitro by Pseudomonas aeruginosa. Medical Science Research 16, 1287-1288.
84. Sulakvelidze, A., Alavidze, Z. and Morris, J.G. Jr (2001) Bacteriophage therapy. Antimicrobial Agents and Chemotherapy 45, 649-659.
85. Summers, W.C. (1993) Cholera and plague in India: the bacteriophage inquiry of 1927-1936. Journal of the History of Medicine and Allied Sciences 48, 275-301.
86. Summers, W.C. (1999) Félix d'Herelle and the Origins of Molecular Biology. Yale University Press, New Haven, CT.
87. Summers, W.C. (2001) Bacteriophage therapy. Annual Reviews in Microbiology 55, 437-451.
88. Thiel, K. (2004) Old dogma, new tricks-21st century phage therapy. Nature Biotechnology 22, 31-36.
89. Verbeken, G., de Vos, D., Vaneechoutte, M., Merabishvili, M., Zizi, M. and Pirnay, J.P. (2007) European regulatory conundrum of phage therapy. Future Microbiology 2, 485-491.
90. Vinodkumar, C., Neelagund, Y. and Kalsurmath, S. (2005) Bacteriophage in the treatment of experimental septicemic mice from a clinical isolate of multidrug resistant Klebsiella pneumoniae. Journal of Communicable Diseases 37, 18-29.
91. Vinodkumar, C., Kalsurmath, S. and Neelagund, Y. (2008) Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian Journal of Pathology and Microbiology 51, 360-366.
92. Wainwright, M. and Swan, H.T. (1986) C.G. Paine and the earliest surviving clinical records of penicillin therapy. Medical History 30, 42-56.
93. Waksman, S.A., Reilly , H.C. and Schatz, A. (1945) Strain specificity and production of antibiotic substances: V. strain resistance of bacteria to antibiotic substances, especially to streptomycin. Proceedings of the National Academy of Sciences USA 31, 157-164.
94. Wang, J., Hu, B., Xu, M., Yan, Q., Liu, S., Zhu, X., Sun, Z., Reed, E., Ding, L. and Gong, J. (2006a) Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. International Journal of Molecular Medicine 17, 309-317.
95. Wang, J., Hu, B., Xu, M., Yan, Q., Liu, S., Zhu, X., Sun, Z., Tao, D., Ding, L. and Reed, E. (2006b) Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum ?-lactamase-producing Escherichia coli bacteremia. International Journal of Molecular Medicine 17, 347-355.
96. Watanabe, R., Matsumot o, T., Sano, G., Ishii, Y., Tateda, K., Sumiyama, Y., Uchiyama, J., Sakurai, S., Matsuzaki, S. and Imai, S. (2007) Efficacy of bacteriophage therapy against gutderived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrobial Agents and Chemotherapy 51, 446-452.
97. Weber-Dabrowska, B., Mulczyk, M. and Górski, A. (2000) Bacteriophage therapy of bacterial infections: an update of our institute's experience. Archivum Immunologiae et Therapiae Experimentalis 48, 547-551.
98. Weber-Dabrowska, B., Mulczyk, M. and Górski, A. (2003) Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplantation Proceedings 35, 1385-1386.
99. Wright, A., Hawkins, C., Änggård, E. and Harper, D. (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clinical Otolaryngology 34, 349-357.